Triodos Investment Management BV Grows Stake in Edwards Lifesciences Co. (NYSE:EW)

Triodos Investment Management BV boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 509,958 shares of the medical research company’s stock after buying an additional 700 shares during the period. Edwards Lifesciences makes up about 3.1% of Triodos Investment Management BV’s holdings, making the stock its 13th largest holding. Triodos Investment Management BV owned 0.09% of Edwards Lifesciences worth $37,752,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in EW. Vanguard Group Inc. raised its position in Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP grew its position in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. State Street Corp grew its holdings in shares of Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after purchasing an additional 256,538 shares during the last quarter. Geode Capital Management LLC lifted its stake in Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after purchasing an additional 284,918 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after buying an additional 696,965 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 0.1 %

Shares of EW opened at $71.17 on Friday. The stock has a market capitalization of $41.84 billion, a price-to-earnings ratio of 10.21, a PEG ratio of 4.82 and a beta of 1.12. The stock has a fifty day moving average of $71.47 and a 200-day moving average of $70.46. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of a number of research analyst reports. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $79.95.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,553 shares of company stock valued at $4,513,064 over the last three months. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.